Tag: Gene Therapy

Neurogene to Advance Multiple Gene Therapy Programs

Neurogene, Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, announced a $68.5 million Series A financing. Invest...

B-MoGen and CytoSen to Develop NK Therapies

B-MoGen Biotechnologies, Inc. and CytoSen Therapeutics announced today a research collaboration to develop the next generation of gene-modified Natural Killer Cell (NK) therapies. B-MoGen will utilize...

CRISPR and ProBioGen to Develop Novel Technologies

CRISPR Therapeutics, a biopharmaceutical company focused on creating gene-based medicines for serious diseases, and ProBioGen, a German service and technology provider, have entered a multi-year resea...

Big Pharma’s Experts Go to Biotech

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca. Vo...

UK Gene Therapy Show Positive Results for Rare Skin Disease

A gene therapy applied to the skin, developed by UK company Amryt Pharma, showed positive preclinical results for the treatment of a rare genetic skin disease. The disease, called recessive dystrop...

British Companies to Develop RALA Gene Therapy Delivery Method

British companies promote the RALA gene therapy delivery method to the immunotherapy market. A collaboration between two companies has been formed in the UK to increase access and decrease the cost...

Gene Therapy Agreement of Sarepta and Aldevron

Strategic relationship is for the supply of plasmid DNA to fulfill Sarepta’s needs for its gene therapy clinical trials and commercial supply. Sarepta Therapeutics and Aldevron have entered into a ...

Bellicum Pharmaceuticals unveiled its first CAR-T candidate

Bellicum Pharmaceuticals, a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, reported safety and promising activity of BPX-601.

SIRION Biotech signed gene therapy deal with Orchard Therapeutics

molecule dev
Orchard has licensed SIRION’s technology to enhance manufacturing efficiency for certain stem cell gene therapy drug candidates.

Orchard Therapeutics is about to build New Gene Therapy Site

Orchard Therapeutics, a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene thera...

AbCellera and Autolus Therapeutics to cooperate on novel CAR-T therapies

AbCellera announced its collaboration with Autolus Therapeutics, a clinical stage biopharmaceutical company developing next-generation programmed T cell therapies.

The first children to receive CAR-T cell therapy in UK

lab dna-test
According to the UK's National Health Service (NHS) the first children to receive a game-changing personalised therapy for cancer will start treatment this week.

Novartis received EU approval for its gene therapy drug

Novartis announced that the European Commission (EC) approved Luxturna, a one-time gene therapy for the treatment of vision loss due to a genetic mutation in both copies of the RPE65 gene.

Cobra Biologics receives a research grant from Innovate UK

Cobra Biologics, an international contract development and manufacturing organization with a focus on advanced therapy medicinal products, has won a £1.5 million shared grant from Innovate UK.

Oxford BioMedica forms a new initiative to optimize drug manufacturing

gene therapy
Oxford BioMedica, a British gene and cell therapy group, announced the formation of a new digital framework initiative to streamline the production of next-generation medicines. The goal of the pro...

European Commission approves a new gene therapy drug

Spark Therapeutics, a commercial gene therapy company, announced that the European Commission has granted marketing authorization for LUXTURNA® (voretigene neparvovec).